Halozyme’s Spotlight Shifts To Enhanze Exclusively After PEGPH20 Fails In Phase III

 
• By Mandy Jackson
  
SC1911_Spotlight_76770868_1200.jpg
After 160 job cuts and with an Enhanze-only focus, Halozyme will be profitable next year. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business